Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory ...

Summary
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1…

2 Articles

Enid News & EagleEnid News & Eagle
Lean Left

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 ...

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency…

Read Full Article
stocktitan.netstocktitan.net

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Monday, May 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cambridge, Massachusetts icon

Cambridge, Massachusetts

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal